Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

229.42 +2.01 (+0.88%)
Streaming Delayed Price Updated: 10:16 AM EST, Nov 29, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts
The FDA approved a supplemental marketing application for Biogen Inc (NASDAQ: BIIB)-Eisai Co Ltd (OTC: ESALY) supporting the traditional approval of Leqembi (lecanemab-irmb), making it the first and... 
Via Benzinga
FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline
The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. 
Via Benzinga
Stock Market Rally Pulls Back As Yields Jump; Tesla, Meta In Focus: Weekly Review
Automakers rallied on sales while Meta's Threads had a big launch. 
Via Investor's Business Daily
FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today
First Solar (FSLR) stock is rising higher on Friday after the solar energy company announced a $1 billion revolving credit facility. 
Via InvestorPlace
Why Is Alibaba (BABA) Stock Up Today?
Alibaba (BABA) stock is on the rise Friday as investors react to a few pieces of news considering the Chinese e-commerce giant. 
Via InvestorPlace
What 29 Analyst Ratings Have To Say About Biogen
Via Benzinga
What's Going On With Biogen Stock Thursday
Biogen Inc (NASDAQ: BIIB) shares were flat in Thursday's after-hours session after falling marginally by 0.31% to $284.99 during  
Via Benzinga
How Is The Market Feeling About Biogen?
Via Benzinga
BIIB Stock Alert: What to Know as FDA Approves Biogen’s Alzheimer’s Drug
Biogen (BIIB) stock is in the news Friday after the pharmaceutical company got approval from the FDA for its Alzheimer's drug. 
Via InvestorPlace
Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move
Via Benzinga
Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval
Via Benzinga
3 Biotech Stocks to Make Your ‘Get Rich’ Dreams Come True
These high return biotech stocks offer tremendous upside ahead and are likely to soar on the back of several growth drivers 
Via InvestorPlace
Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment
The FDA is expected to announce Thursday whether it has approved or rejected Biogen's Alzheimer's drug. 
Via Investor's Business Daily
A Look Into Biogen Inc's Price Over Earnings
Via Benzinga
$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
Biogen is counting on Leqembi to boost its revenue growth. 
Via The Motley Fool
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
Biogen Inc (NASDAQ: BIIB) announced new Spinraza (nusinersen) data that were presented at the SMA Research & Clinical Care Meeting  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?
The catalyst many Biogen investors have been waiting for may soon arrive. 
Via The Motley Fool
Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment. 
Via The Motley Fool
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
Via Benzinga
How to Retire Rich: Biotech Stocks Edition
Thanks to its enormous and practically permanent relevancies, the biotech sector offers a great avenue for retirement planning stocks. 
Via InvestorPlace
2 Market-Beating Stocks With Major Catalysts on the Way
Can these companies keep climbing? 
Via The Motley Fool
7 Undervalued S&P 500 Stocks to Buy in June
If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you. 
Via InvestorPlace
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health... 
Via Benzinga
Why Biogen Stock Is Trading Down Today
Biogen Inc. (NASDAQ: BIIB) shares fell Tuesday after it was deemed that the ability of the company's Alzheimer's drug, Leqembi, to slow cognitive decline may not outweigh its risks, according to... 
Via Benzinga
Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
Benzinga 
Via Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.